Evidence map›Paper›PMID 37808458›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients.

Auli Verkkoniemi-Ahola, Päivi Hartikainen, Katja Hassi, Hanna Kuusisto, Sanni Lahdenperä, Juha Mehtälä, Matias Viitala, Tero Ylisaukko-Oja, Merja Soilu-Hänninen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Auli Verkkoniemi-AholaDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Päivi HartikainenNeuro Center, Neurology Outpatient Clinic, Kuopio University Hospital, Kuopio, Finland.
Katja HassiBiogen Finland Oy, Espoo, Finland.
Hanna KuusistoDepartment of Neurology, Tampere University Hospital, Tampere, Finland.ORCID https://orcid.org/0000-0002-3697-4961
Sanni LahdenperäBiogen Finland Oy, Espoo, Finland.ORCID https://orcid.org/0000-0001-7306-3502
Juha MehtäläMedEngine Oy, Helsinki, Finland.
Matias ViitalaStellarQ Ltd, Turku, Finland.
Tero Ylisaukko-OjaMedEngine Oy, Helsinki, Finland.
Merja Soilu-HänninenDepartment of Clinical Neurosciences, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0001-6930-0229
Kuopio University Hospital · FIUniversity of Eastern Finland · FIUniversity of Helsinki · FIUniversity of Oulu · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The primary objective was to evaluate long-term treatment persistence and safety of natalizumab in Finnish multiple sclerosis patients. The secondary objectives were to assess patient characteristics, use of natalizumab-related safety protocol, and treatment persistence in patients with different anti-John Cunningham virus antibody statuses (John Cunningham virus status). Materials & Methods: All adult multiple sclerosis patients in the Finnish multiple sclerosis register who started natalizumab between 1/2006 and 12/2018 were included in this study and followed retrospectively until treatment discontinuation or end of follow-up (12/2019). Results: In total, 850 patients were included. Median duration of natalizumab treatment was 7.8 years in John Cunningham virus negative ( Conclusions: Treatment persistence was very high among John Cunningham virus negative patients. The study supports long-term effectiveness of natalizumab and a washout duration of less than 6 weeks after discontinuation.

Indexed as

clinical decision-makingduration of therapyJohn Cunningham virusMultiple sclerosisnatalizumabretrospective studies

Identifiers

PMID37808458
PMCPMC10552456
OpenAlexW4387344198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.